Conversely, clearance of MRD after completion of initial chemotherapy may identify some patients, including those with NPM1-mutated AML regardless of FLT3-ITD status, intermediate-risk AML without NPM1 mutation, or de novo AML with myelodysplasia-related gene mutations, who do not benefit from immediate allogeneic HCT [76,77,78,79]. The gene discussed is NPM1; the disease is Myelodysplasia.